logo-loader
viewAdmedus Ltd

Admedus secures $6 million to expand medical technologies strategy

The placement to institutional and sophisticated investors will be followed by a share purchase plan for existing shareholders.

Laboratory tests
The company is accelerating the commercialisation of new products

Admedus Ltd (ASX:AHZ) has raised about $6 million after securing commitments from institutional and sophisticated investors in a placement at 30 cents per share.

The medical technologies company has also invited existing shareholders to participate in a share purchase plan (SPP).

This offers the opportunity to subscribe for up to $15,000 worth of new Admedus shares at an issue price of 30 cents per share.

READ: Admedus has healthy mix of reliable Infusion earnings and strong revenue growth from ADAPT

Funds raised will enable the company to expand and progress its strategic projects, including the acceleration of its 3D product portfolio from development to commercialisation.

CEO Wayne Paterson said: “The capital raising follows growing interest from sophisticated institutional investors who value Admedus as an exciting and credible investment opportunity recognising the potential of our unique product portfolio.”

Business transformation

Admedus has undergone a dramatic transformation and experienced unprecedented levels of growth during the past 18 months.

The company has delivered record sales and revenue growth across its ADAPT and infusion product lines, and has restructured key business units.

Entry into emerging markets

It has also secured entry into significant emerging markets and expanded product offerings with the introduction of the ground-breaking 3D shaped tissue franchise.

 

 

Paterson said: “Since the implementation of our new strategy, the company has worked diligently across all areas to improve efficiencies, reduce expenses and elevate the reputation and credibility of the business within the global medtech sector.”

Admedus recently submitted multiple IP applications in the US as it targets entry into the lucrative TAVR market, currently worth US$3.5 billion and expected to grow to US$5 billion by 2020.

READ: Admedus appoints medtech expert Michael Oswell as vice president, development

“We are only just beginning to explore the full potential of our unique shaped tissue technology with 16 potential new products in the pipeline, each one leveraging the benefits of our clinically-superior ADAPT technology,” Paterson said.

“Momentum continues to build across the business with recent announcements including the appointment of a new VP - Development, applications for additional product patents and the signing of a letter of intent to provide alternative funding for our immunotherapies division.”

Quick facts: Admedus Ltd

Price: 0.0865 AUD

ASX:AHZ
Market: ASX
Market Cap: $51.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

3 min read